Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Adjuvant Chemotherapy in HCC after Liver Transplantation
NCT02580253Phase 2Withdrawn
- Sponsor
- Zhejiang University
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, gemcitabine, irinotecan, paclitaxel, docetaxel and 3 more in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Planned start Nov 2017; status: withdrawn.
02
Drugs
oxaliplatingemcitabineirinotecanpaclitaxeldocetaxel
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02580253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580253.